



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

MYELOMAS

*Personalized Prognosis
and Precision Medicine Approaches
for Enhanced Patient Care
in Multiple Myeloma*

10th - 11th OCTOBER, 2025

📍 The Hive Hotel, ROME

PRESIDENTS

Claudio Cerchione and Gerardo Musuraca

HONORARY PRESIDENTS

Nicola Normanno

SCIENTIFIC COMMITTEE

**Claudio Cerchione, Delia Cangini,
Michela Ceccolini, Sofia Cortesi,
Alessandro Lucchesi,
Giovanni Martinelli, Matteo Marchesini,
Gerardo Musuraca, Davide Nappi,
Sonia Ronconi, Alice Rossi**

Organizing Secretariat



Provider n. 2773

Registration

Download the “PROEVENTI” app on your smartphone.



Login or create a new account

Enter the event pin: MYELOMAS25

You are now on the event page, click on **“REGISTRATION”** at the top left

The Conference has been accredited to the Italian Ministry of Health:

Event n. 458081 Provider n. 2773

ECM Credits n. 12 for:

Medical Surgeon (interdisciplinary area), Biologist, Pharmacist, TSLB, Nurse

Training objective 3: Clinical documentation. Diagnostic and rehabilitation clinical-care pathways, care profiles - treatment profiles.


Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.

**Participation at the event is free of charge, but registration is compulsory.
The registration deadline is 10 Oct 2025**



PROMOTED BY



**SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

PATRONAGE



SIE
**Società Italiana
di Ematologia**



FACULTY

BAHLIS NIZAR	UNIVERSITY OF CALGARY
BEILHACK ANDREAS	UNIVERSITY OF WUERZBURG
BOTTA CIRINO	UNIVERSITA' DEGLI STUDI DI PALERMO
BRUNO BENEDETTO	AOU CITTA' DELLA SALUTE E DELLA SCIENZA - TORINO
BUDA GABRIELE	AZIENDA OSPEDALIERO-UNIVERSITARIA DI PISA
CANGINI DELIA	IRCCS IRST- MELDOLA (FC)
CAVO MICHELE	ALMA MATER STUDIOURUM UNIVERSITA' DI BOLOGNA
CECCOLINI MICHELA	IRCCS IRST - MELDOLA (FC)
CELLINI CLAUDIA	OSPEDALE S. MARIA DELLE CROCI - RAVENNA
CERCHIONE CLAUDIO	IRCCS IRST - MELDOLA (FC)
CORTESI SOFIA	IRCCS IRST - MELDOLA (FC)
DERUDAS DANIELE	OSPEDALE ARMANDO BUSINCO - CAGLIARI
DESANTIS VANESSA	UNIVERSITA' DI BARI ALDO MORO
DIMOPOULOS MELETIOS A.	UNIVERSITY OF ATHENS
DURIE BRIAN	CEDARS SINAI MEDICAL CENTER - LOS ANGELES
GHOBRIAL IRENE	DANA-FARBER CANCER INSTITUTE/HARVARD MEDICAL SCHOOL - BOSTON
LEE HANS CHARLES	SARAH CANNON RESEARCH INSTITUTE - NASHVILLE
LONIAL SAGAR	EMORY UNIVERSITY SCHOOL OF MEDICINE - ATLANTA
LUCCHESI ALESSANDRO	IRCCS IRST- MELDOLA (FC)
MARCHESINI MATTEO	IRCCS IRST - MELDOLA (FC)
MARTINELLI GIOVANNI	ALMA MATER STUDIOURUM UNIVERSITA' DI BOLOGNA
MATEOS MARIA VICTORIA	UNIVERSITY OF SALAMANCA
MONTEFUSCO VITTORIO	IRCCS ISTITUTO NAZIONALE DEI TUMORI - MILANO
MOREAU PHILIPPE	UNIVERSITY OF NANTES
MUSURACA GERARDO	IRCCS IRST - MELDOLA (FC)
NAPPI DAVIDE	IRCCS IRST - MELDOLA (FC)
NERI PAOLA	UNIVERSITY OF CALGARY
NORMANNO NICOLA	IRCCS IRST - MELDOLA (FC)
RICHARDSON PAUL	DANA-FARBER CANCER INSTITUTE/HARVARD MEDICAL SCHOOL - BOSTON
RICHTER JOSHUA	TISCH CANCER INSTITUTE, MOUNT SINAI - NEW YORK
ROMANO ALESSANDRA	UNIVERSITA' DEGLI STUDI DI CATANIA
RONCONI SONIA	IRCCS IRST - MELDOLA (FC)
ROSSI ALICE	IRCCS IRST - MELDOLA (FC)
ROTONDO FRANCESCO	OSPEDALE INFERMI DI RIMINI
SCHJESVOLD FREDRIK	OSLO MYELOMA CENTER
SOLIMANDO ANTONIO	UNIVERSITA' DI BARI ALDO MORO
TERRAGNA CAROLINA	IRCCS POLICLINICO SANT'ORSOLA - BOLOGNA
ZAMBELLO RENATO	SCUOLA DI MEDICINA E CHIRURGIA - PADOVA



KEY INFORMATION

VENUE

The Hive Hotel – Roma

Via Torino 6, Stazione Termini, 00184 Roma ,Italia

INTERNET

WiFi is available in all areas.



GENERAL INFORMATION

LANGUAGE

The official language during the congress is English, therefore, all presentations will be given in English.

CLIMATE

The average temperature is around 16–27 degrees.

BANKING SERVICE

The official currency in Rome is the Euro. Foreign currencies can be exchanged at banks, which are usually open from Monday to Friday from 08:30 to 13:30.

HOTEL INFORMATION

For hotel information and reservations please visit the Hotels & Groups Desk.

TAXI

The single number to call a taxi is 060609

For other utilities on the taxi service, see www.060608.it

The journey to/ from Fiumicino Airport: 48€

The journey to/ from Ciampino Airport: 30€



PUBLIC TRANSPORT





From Termini Station, you can get to the hotel on foot in a few minutes, exiting the main exit, Piazza dei Cinquecento.

From here heading to the left and crossing the road at the traffic light, go to Via Massimo D'Azeglio and walk it for about 250 meters.

From here turn right on Via Torino and walk it for 20 meters.

Welcome to come!





10
10.25

08.30 – 09.00 WELCOME

C. Cerchione, G. Musuraca, N. Normanno

SESSION 1

NEW INSIGHTS INTO THE BIOLOGY OF PLASMA CELLS DISCRASIAS

Chairs: G. Martinelli, A. Romano

09.00 – 09.20: From research to the clinical practice: the milestones of Myeloma biology

A. Romano

09.20 – 09.40: Cellular circuitries in the extra medullary disease

A.G. Solimando

09.40 – 10.00: Unmasking novel biomarkers to sketch future trajectories in Multiple Myeloma therapy

V. Desantis

10.00 – 10.30: Coffee Break

SESSION 2

HOW TO STRATIFY THE RISK IN THE ERA OF ULTRA-NOVEL AGENTS

Chairs: C. Cerchione, M. Cavo, B. Durie, S. Lonial

10.30 – 11.00: What we have learnt from iSTOPMM?

B. Durie

11.00 – 11.30: MGUS: how to manage?

S. Lonial

11.30 – 12.00: Smoldering Myeloma: how to manage?

M.V. Mateos

12.00 – 12.30: Biology of pre-myelomas: what is changing?

I. Ghobrial

12.30 – 13.40: Lunch

Friday, Oct 10

SESSION 3

OPEN QUESTIONS: WHERE ARE WE GOING?

Chairs: J. Richter, A.G. Solimando

13.40 – 14.00: Building on Anti-CD38 regimens to optimize outcome

P. Richardson

14.00 – 14.30: Should we continue to transplant myeloma?

J. Richter

14.30 – 14.50: How I manage Transplant-ineligible patients

C. Cerchione

14.50 – 15.20: Coffee Break

SESSION 4

MANAGEMENT OF MULTIPLE MYELOMA - POST-FRONTLINE SETTING

Chairs: M. Cavo, S. Lonial, V. Montefusco

DEBATE: The evolving landscape of maintenance therapy

Referee: S. Lonial

15.20 – 15.40: Until progression M. Cavo


versus

15.40 – 16.00: Fixed duration/MRD-driven V. Montefusco

16.00 – 16.30: How to evaluate MRD and why?

C. Terragna

16.30: *Closing of Day 1* – C. Cerchione, G. Musuraca

A 3D illustration of a blood clot, which is a dark, irregular mass with a fibrous texture, surrounded by numerous red blood cells. The red blood cells are depicted as biconcave discs with a reddish-pink color and a slight shadow, giving them a three-dimensional appearance. The background is a warm, orange-red gradient.

11

10.25

09.00 WELCOME TO DAY 2

C. Cerchione, G. Musuraca

SESSION 5

FROM GUIDELINES TO CLINICAL PRACTICE

Chairs: G. Musuraca, B. Durie, S. Lonial

09.00 – 09.20: Special Lecture: Allogenic stem cell transplantation in multiple myeloma and therapy: related myeloid neoplasms

B. Bruno

Special Lecture: EHA-EMN-IMWG Guidelines: What is changing?

09.20 – 09.50: Treatment in frontline setting **P. Moreau**

09.50 – 10.20: Treatment of relapsed/refractory patients **M. Dimopoulos**

10.20 – 10.40: Coffee Break

SESSION 6

NEW ERA OF IMMUNOTHERAPY

Chairs: C. Cellini, C. Cerchione, F. Rotondo

10.40 – 11.00: All about Bispecific antibodies and how to integrate in daily practice

C. Cerchione

11.00 – 11.20: All about CAR-T and how to integrate in daily practice

B. Bruno

11.20 – 11.40: Long term toxicities and infectious prophylaxis in Multiple Myeloma (including vaccinations)

C. Botta

11.40 – 12.00: Linking the biology to the clinical decisions in Smouldering and active Myeloma

N. Bahlis, P. Neri

Saturday, Oct 11

12.00 – 12.20: Lecture: New mechanisms of disease resistance to T-cell based therapies

P. Richardson

12.20 – 13.20: Lunch

SESSION 7

PARTICULAR SETTINGS AND SITUATIONS

Chairs: D. Cangini, H.C. Lee, F. Schjesvold

13.20 – 13.40: Extra medullary disease

D. Derudas

13.40 – 14.00: Diagnosis and management of amyloidosis

H.C. Lee

14.00 – 14.20: Diagnosis and management of plasma cell leukemia

F. Schjesvold

SESSION 8

NEXT STEPS IN PERSONALIZED MEDICINE IN MULTIPLE MYELOMA

Chairs: M.Ceccolini, A. Lucchesi

14.20 – 14.40: The role of combined imaging in Smoldering and Multiple Myeloma

A. Rossi

14.40 – 15.00: Gene expression profiling plus integrated multidisciplinary approach, to detect new risk adapted prognostic index in Multiple Myeloma (and SMM) – The GIMPI Project

M. Marchesini

SESSION 9

NOVEL AGENTS ON THE HORIZON

Chairs: A.G. Beilhack, G. Buda, R. Zambello

15.00 – 15.20: XPO-1 inhibition

G. Buda

15.20 – 15.40: Anti-BCMA

H.C. Lee

15.40 – 16.00: Peptide-drug conjugates

R. Zambello

16.00 – 16.30: **Lecture: New and emerging targets**

A.G. Beilhack

16.30: *Closing of Day 2 and See you next year*

C. Cerchione, G. Musuraca

SCIENTIFIC RATIONALE

In the last decades, survival rates of Multiple Myeloma have been brilliantly improved thanks to the introduction of novel agents: patients diagnosed after 2010 have had higher rates of novel therapy use and better survival outcomes compared with those of earlier years. Most relevant therapeutic advances over the past decades has been the introduction of novel therapies, such as immune modifying agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), adopted with or without stem cell transplantation. Moreover, in the last few years, the MM therapeutic “toolbox” has improved further with the approval in new generation IMiD (pomalidomide), the monoclonal antibodies, daratumumab and elotuzumab, as well as the new-generation proteasome inhibitors, carfilzomib and ixazomib, waiting for introduction in daily practice of novel agents with new mechanism of action (Belantamab, CAR-T). At the same time, there is increasing understanding of MM tumor biology, creating the rationale for new combinations of drugs and new therapy development. Discovery of the associated cytogenetic abnormalities confirm the hypothesis that MM is a heterogeneous disease, suggesting that riskadapted therapies and individualizing treatment will further help improve patient management. The aim of this event is the discussion between international and national experts.

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

SILVER



Johnson & Johnson




BRONZE

AstraZeneca 

SANDOZ

sanofi



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

MYELOMAS

*Personalized Prognosis
and Precision Medicine Approaches
for Enhanced Patient Care
in Multiple Myeloma*

graphic design: Mario Titone
info@mariotitone.com